Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-32 (Cancelled)

33. (Currently amended) A method for reducing colonization of enterohemorragic *Escherichia coli* (EHEC) in a mammal comprising administering to said ruminant a therapeutically effective amount of a composition comprising an EHEC cell culture supernatant.

34. (Currently amended) A method for reducing shedding of enterohemorragic *Escherichia coli* (EHEC) from a mammal comprising administrating to said ruminant a therapeutically effective amount a composition comprising an EHEC cell culture supernatant.

35. (New) The method of claim 33, wherein the mammal is a ruminant.

36. (New) The method of claim 35, wherein the ruminant is a bovine subject.

37. (New) The method of claim 33, wherein the composition further comprises an immunological adjuvant.

38. (New) The method of claim 33, wherein the EHEC is EHEC O157:H7.

39. (New) The method of claim 33, wherein the EHEC is EHEC O157:NM.

40. (New) The method of claim 37, wherein the immunological adjuvant comprises an oil-in-water emulsion.

41. (New) The method of claim 40, wherein the immunological adjuvant comprises a mineral oil and dimethyldioctadecylammonium bromide.

42. (New) The method of claim 41, wherein the immunological adjuvant is VSA3.

43. (New) The method of claim 42, wherein the VSA3 is present in the composition at a concentration of about 20% to about 40% (v/v).

44. (New) The method of claim 43, wherein the VSA3 is present in the composition at a concentration of about 30% (v/v).

45. (New) The method of claim 33, wherein the composition further comprises one or more recombinant or purified EHEC antigens selected from the group consisting of EspA, EspB, EspD, Tir and Intimin.

46. (New) The method of claim 45, wherein EspA + Tir comprise at least 20% of the cell protein present in the composition.

47. (New) The method of claim 37, wherein the composition further comprises one or more recombinant or purified EHEC antigens selected from the group consisting of EspA, EspB, EspD, Tir and Intimin.

48. (New) The method of claim 47, wherein EspA + Tir comprise at least 20% of the cell protein present in the composition.

49. (New) The method of claim 34, wherein the mammal is a ruminant.

50. (New) The method of claim 49, wherein the ruminant is a bovine subject.

51. (New) The method of claim 34, wherein the composition further comprises an immunological adjuvant.

52. (New) The method of claim 34, wherein the EHEC is EHEC O157:H7.

53. (New) The method of claim 34, wherein the EHEC is EHEC O157:NM.

54. (New) The method of claim 51, wherein the immunological adjuvant comprises an oil-in-water emulsion.

55. (New) The method of claim 54, wherein the immunological adjuvant comprises a mineral oil and dimethyldioctadecylammonium bromide.

56. (New) The method of claim 55, wherein the immunological adjuvant is VSA3.

57. (New) The method of claim 56, wherein the VSA3 is present in the composition at a concentration of about 20% to about 40% (v/v).

58. (New) The method of claim 57, wherein the VSA3 is present in the composition at a concentration of about 30% (v/v).

59. (New) The method of claim 34, wherein the composition further comprises one or more recombinant or purified EHEC antigens selected from the group consisting of EspA, EspB, EspD, Tir and Intimin.

60. (New) The method of claim 59, wherein EspA + Tir comprise at least 20% of the cell protein present in the composition.

61. (New) The method of claim 51, wherein the composition further comprises one or more recombinant or purified EHEC antigens selected from the group consisting of EspA, EspB, EspD, Tir and Intimin.

62. (New) The method of claim 61, wherein EspA + Tir comprise at least 20% of the cell protein present in the composition.